HOME » News & Media

    Vyome Biosciences to Present Corporate and Pipeline Overview at BIO International Convention

     

    New Delhi, June 16, 2017: Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, today announced that Venkateswarlu Nelabhotla (N. Venkat), co-founder and chief executive officer of Vyome, will present at the 2017 Biotechnology Innovation Organization’s (BIO) International Convention in San Diego, Calif. N. Venkat presents at 2 p.m. PT on Thursday, June 22.

    N. Venkat will present on Vyome’s innovative platforms and novel, unique pipeline of drug candidates designed to address antibiotic resistant and opportunistic skin pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment option being studied in phase 2 trials for the treatment of antibiotic resistant acne.
    VB 1953, the company’s lead drug candidate, is a potent next-generation antibiotic and anti-inflammatory compound combined with a patented micro-technology gel system designed to maximize effect at the site of infection and minimize systemic exposure. In a U.S.-based phase 1 clinical trial in patients with moderate to severe acne, VB 1953 met its primary endpoint relative to pharmacokinetics, achieving plasma concentration less than 1 ng/ml, was generally well tolerated and showed anti-acne and anti-inflammatory properties. Vyome has completed enrollment in its Proof of Concept clinical study and plans to initiate a phase 2B trial to further evaluate VB 1953 for the treatment of moderate to severe acne by the end of 2017.

    About Vyome Biosciences
    Vyome Biosciences is an innovation-driven, clinical stage bio-pharmaceutical company, which has novel platforms technologies and a deep pipeline of novel drugs for antibiotic resistant acne, and other skin opportunistic pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for antibiotic resistant acne being studied in phase 2 trials. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance, and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. Follow us on Twitter @VyomeBio.

    About BIO International Convention
    The BIO International Convention is the largest gathering among the biopharmaceutical industry, and will be attended by more than 16,000 professionals from more than 3,100 companies worldwide. The convention will highlight innovation in biopharma with fireside chats, partnering meetings, company presentations and exhibitors from all fields.

    Visit: www.vyome.in
    Copyright © 2017 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Biosciences. All rights reserved.